Unimed, Watson, Par settle AndroGel testosterone gel patent litigation

By Angela McDaniels

Seattle, Sept. 13 - Unimed Pharmaceuticals, Inc. said it settled all patent litigation with Watson Pharmaceuticals, Inc. and Par Pharmaceutical Cos. Inc. in connection with each company's abbreviated New Drug Application for a generic version of AndroGel testosterone gel 1% CIII, to which Marietta, Ga.-based Unimed holds exclusive U.S. rights under a license with Laboratories Besins Iscovesco.

AndroGel is approved in the United States for replacement therapy in men with conditions associated with low or absent levels of endogenous testosterone.

Unimed parent Solvay Pharmaceuticals, Inc. entered into separate long-term commercial agreements with Corona, Calif.-based Watson and Woodcliff Lake, N.J.-based Par under which a generic version of AndroGel may be marketed beginning in 2015, which is five years prior to Unimed's patent expiry.

In addition, Solvay entered into a co-promotion agreement with Watson, under which Watson will promote the product to urologists through its U.S. sales representatives, and an agreement with Par under which Solvay will use Par's branded sales force to co-promote AndroGel for six years and Par will manufacture a back-up supply of AndroGel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.